CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Balance Sheet
NASDAQ:CNTA - US1523091007 - ADR
17 USD
-0.01 (-0.06%)
17 USD
0 (0%)
| MRQ (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | 383.22M | 128.03M | 393.60M | 595.10M | |||
| Marketable Securities | N/A | 98.96M | 128.52M | N/A | N/A | |||
| Receivables | 44.00M | 45.00M | 39.00M | 26.70M | 16.80M | |||
| Other Current Assets | 5.54M | 8.93M | 19.62M | 17.40M | 16.90M | |||
| Total Current Assets | 300.00M | 536.00M | 315.00M | 437.70M | 628.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 11.00M | 12.00M | 13.00M | 1.20M | 200.00K | |||
| Investments And Advances | 153.00M | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 1.72M | 2.05M | 2.55M | 5.40M | 700.00K | |||
| Total Non-Current Assets | 192.00M | 41.00M | 45.00M | 6.60M | 800.00K | |||
| TOTAL ASSETS | 492.00M | 577.00M | 360.00M | 444.30M | 629.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | 0.00 | |||
| Accrued Expenses | 24.00M | 50.00M | 27.00M | 22.90M | 15.80M | |||
| Accounts Payable | 5.69M | 7.14M | 12.00M | 13.80M | 8.10M | |||
| Other Current Liabilities | 260.00K | 840.00K | 110.00K | 1.60M | 800.00K | |||
| Total Current Liabilities | 30.00M | 58.00M | 39.00M | 38.30M | 24.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 110.00M | 109.00M | 76.00M | 69.80M | 75.70M | |||
| Other Non-Current Liabilities | 7.97M | 8.32M | 8.92M | 0.00 | 37.70M | |||
| Total Non-Current Liabilities | 117.00M | 117.00M | 85.00M | 69.80M | 113.50M | |||
| TOTAL LIABILITIES | 147.00M | 175.00M | 124.00M | 108.10M | 138.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.06B | -989.00M | -753.00M | -601.90M | -385.70M | |||
| Additional Paid In Capital | 1.41B | 1.39B | 987.00M | 939.30M | 876.30M | |||
| Common Shares | 360.00K | 360.00K | 270.00K | 300.00K | 300.00K | |||
| Other Shareholders' Equity | 1.59M | 4.21M | 1.49M | -1.50M | 700.00K | |||
| Shares Outstanding | 134.07M | 133.07M | 99.05M | 94.85M | 90.05M | |||
| Tangible Book Value per Share | N/A | 3.03 | 2.39 | 3.55 | 5.46 | |||
| Total Shareholders' Equity | 345.00M | 402.00M | 236.00M | 336.20M | 491.60M | |||
| TOTAL LIABILITIES AND EQUITY | 492.00M | 577.00M | 360.00M | 444.30M | 629.60M | |||
| Statistics | ||||||||
| Debt/Equity | 0.32 | 0.27 | 0.32 | 0.21 | 0.15 | |||
| Current Ratio | 10.00 | 9.24 | 8.08 | 11.43 | 25.56 | |||
| Return On Assets (ROA) | -46.75% | -40.90% | -41.94% | -48.66% | -60.53% | |||
| Return On Equity (ROE) | -66.67% | -58.71% | -63.98% | -64.31% | -77.52% | |||
All data in USD , ROIC based on taxRate of 0.21